Log in
NASDAQ:CERC

Cerecor Stock Forecast, Price & News

$2.78
-0.06 (-2.11 %)
(As of 09/19/2020 12:07 AM ET)
Add
Compare
Today's Range
$2.71
Now: $2.78
$2.96
50-Day Range
$2.20
MA: $2.61
$3.07
52-Week Range
$1.52
Now: $2.78
$6.19
Volume1.97 million shs
Average Volume381,263 shs
Market Capitalization$208.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CERC
CUSIPN/A
Phone410-522-8707

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.75 million
Book Value$0.40 per share

Profitability

Net Income$-16,070,000.00

Miscellaneous

Employees64
Market Cap$208.22 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$2.78
-0.06 (-2.11 %)
(As of 09/19/2020 12:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerecor (NASDAQ:CERC) Frequently Asked Questions

How has Cerecor's stock price been impacted by COVID-19 (Coronavirus)?

Cerecor's stock was trading at $2.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CERC shares have increased by 15.4% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cerecor?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerecor
.

When is Cerecor's next earnings date?

Cerecor is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Cerecor
.

How were Cerecor's earnings last quarter?

Cerecor Inc (NASDAQ:CERC) announced its earnings results on Thursday, August, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.05. The firm earned $1.34 million during the quarter, compared to analyst estimates of $2.25 million.
View Cerecor's earnings history
.

What price target have analysts set for CERC?

4 brokers have issued twelve-month target prices for Cerecor's stock. Their forecasts range from $10.00 to $12.00. On average, they expect Cerecor's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 277.7% from the stock's current price.
View analysts' price targets for Cerecor
.

Who are some of Cerecor's key competitors?

What other stocks do shareholders of Cerecor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), AEterna Zentaris (AEZS), BioNano Genomics (BNGO), KushCo (KSHB), OrganiGram (OGI), Novan (NOVN), Pennsylvania R.E.I.T. (PEI) and Zosano Pharma (ZSAN).

Who are Cerecor's key executives?

Cerecor's management team includes the following people:
  • Ms. Mariam E. Morris, Consultant (Age 51)
  • Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
  • Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
  • Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
  • Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

Who are Cerecor's major shareholders?

Cerecor's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.59%), Opaleye Management Inc. (4.50%), Ikarian Capital LLC (0.54%), Nuveen Asset Management LLC (0.21%), Goldman Sachs Group Inc. (0.19%) and Assenagon Asset Management S.A. (0.19%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Cerecor Inc, Christopher Ryan Sullivan, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Michael F Cola, Pericles Calias and Simon Pedder.
View institutional ownership trends for Cerecor
.

Which institutional investors are selling Cerecor stock?

CERC stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and UBS Group AG.
View insider buying and selling activity for Cerecor
.

Which institutional investors are buying Cerecor stock?

CERC stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Opaleye Management Inc., Goldman Sachs Group Inc., Assenagon Asset Management S.A., Nuveen Asset Management LLC, Two Sigma Advisers LP, Bank of New York Mellon Corp, and Jane Street Group LLC. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Christopher Ryan Sullivan, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Michael F Cola, Pericles Calias, and Simon Pedder.
View insider buying and selling activity for Cerecor
.

How do I buy shares of Cerecor?

Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $2.78.

How big of a company is Cerecor?

Cerecor has a market capitalization of $208.22 million and generates $6.75 million in revenue each year. The company earns $-16,070,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. Cerecor employs 64 workers across the globe.

What is Cerecor's official website?

The official website for Cerecor is www.cerecor.com.

How can I contact Cerecor?

Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.